Coram acquisition is in line with CVS Caremark's strategy

CVS Caremark is looking to acquire Coram, the specialty infusion services and enteral nutrition business unit of Apria Healthcare Group, for roughly $2.1 billion. Coram provides infusion therapies and nutrition services to more than 20,000 patients each month.

The acquisition is a significant move for CVS Caremark given the growth of the home infusion business and specialty pharmacy. Furthermore, it enables CVS Caremark to further leverage its “integration sweet spots” and is in line with the company’s strategy of investing in core businesses that will help drive growth.

The infusion services market is estimated to be around $11 billion and the acquisition will undoubtedly enable CVS Caremark to compete in the growing market as specialty infusion drugs account for a significant portion of new drugs in the pipeline.

CVS Caremark executives have long expressed the company’s commitment to expanding its role in specialty pharmacy. Specialty currently represents about 20% of the total drug spend today, but that number is projected to rise to more to than 30% by the end of the decade.

As the company has stated, this move enables CVS Caremark to be a full-service specialty provider and helps the retailer bring new approaches to market that improve the management of specialty pharmacy costs that are covered through the medical or pharmacy benefit, depending on the site of care.


Login or Register to post a comment.